دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization.
Mack, Philip C. MD 1,; Hirsch, Fred R. MD, PhD 1,; Bunn, Paul A. MD 2,; Minna, John D. MD 3,,
doi : 10.1200/JCO.22.01136
Volume 40(33) pgs. 3787-3901 November 20, 2022
Surveillance Strategies in Endometrial Cancer Care: Why Less Represents Progress.
Beavis, Anna L. MD, MPH 1,; Fader, Amanda N. MD 1,,
doi : 10.1200/JCO.22.01551
Ki67 as a Companion Diagnostic: Good or Bad News?.
Dowsett, Mitch PhD 1,,; Nielsen, Torsten O. MD 2,; Rimm, David L. MD 3,; Hayes, Daniel F. MD 4,; on behalf of the International Ki67 in Breast Cancer Working Group
doi : 10.1200/JCO.22.00581
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker, Uwe MD 1,,; Gotze, Katharina S. MD 2,; Kiewe, Philipp MD 3,; Germing, Ulrich MD 4,; Mayer, Karin MD 5,; Radsak, Markus MD 6,; Wolff, Thomas MD 7,; Chromik, Joerg MD 8; Sockel, Katja MD 9,; Oelschlagel, Uta PhD 9; Haase, Detlef PhD 10,; Illmer, Thomas MD 11,; Al-Ali, Haifa Kathrin MD 12,13,; Silling, Gerda MD 14,; Reynolds, Joseph G. PhD 15,; Zhang, Xiaosha PhD 15,; Attie, Kenneth M. MD 15,; Shetty, Jeevan K. MD 16,; Giagounidis, Aristoteles MD 17,
doi : 10.1200/JCO.21.02476
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
Valanparambil, Rajesh M. PhD 1,2; Carlisle, Jennifer MD 3,; Linderman, Susanne L. PhD 1,2; Akthar, Akil PhD 1,2; Millett, Ralph Linwood MD 3,; Lai, Lilin MS 1,4,5; Chang, Andres MD, PhD 1,2,3,6; McCook-Veal, Ashley A. MS 7; Switchenko, Jeffrey PhD 8; Nasti, Tahseen H. PhD 1,2; Saini, Manpreet MS 1,2,9; Wieland, Andreas PhD 1,2,10,11,; Manning, Kelly E. MS 1,4,5; Ellis, Madison MS 1,4,5; Moore, Kathryn M. PhD 1,4,5; Foster, Stephanie L. MS 1,4,5,; Floyd, Katharine MS 1,4,5; Davis-Gardner, Meredith E. PhD 1,4,5,; Edara, Venkata-Viswanadh PhD 1,4,5; Patel, Mit MS 1,4,5; Steur, Conor MD 3,6,; Nooka, Ajay K. MD 3,6,; Green, Felicia MS 3; Johns, Margaret A. PhD 3,; O'Brein, Fiona MS 3; Shanmugasundaram, Uma PhD 3,6; Zarnitsyna, Veronika I. PhD 1,12,; Ahmed, Hasan MS 1,12; Nyhoff, Lindsay E. PhD 1,13; Mantus, Grace MS 1,13; Garett, Michael MS 2,14; Edupuganti, Srilatha MD 2,14,; Behra, Madhusmita PhD 3; Antia, Rustom PhD 1,12; Wrammert, Jens PhD 1,13; Suthar, Mehul S. PhD 1,4,5,; Dhodapkar, Madhav V. MD 3,6,; Ramalingam, Suresh MD 3,; Ahmed, Rafi PhD 1,2,,
doi : 10.1200/JCO.21.02986
AB PURPOSE: To examine COVID-19 mRNA vaccine-induced binding and neutralizing antibody responses in patients with non-small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after the primary 2-dose and booster vaccination.
Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial.
Zola, Paolo MD 1,; Ciccone, Giovannino MD, PhD 2; Piovano, Elisa MD, PhD 3,; Fuso, Luca MD, PhD 4,; Di Cuonzo, Daniela MSc, PhD 2; Castiglione, Anna MSc 2; Pagano, Eva MSc 2; Peirano, Elena MD 1; Landoni, Fabio MD 5; Sartori, Enrico MD 6; Narducci, Fabrice MD 7; Bertetto, Oscar MD 8; Ferrero, Annamaria MD, PhD 4,; the TOTEM Collaborative Group
doi : 10.1200/JCO.22.00471
AB PURPOSE: In the absence of clear evidence from randomized trials, the intensity of follow-up regimens after surgical treatment of endometrial cancer is highly variable in clinical practice. To reduce this uncertainty, we conducted a randomized trial to test whether an intensive (INT) versus a minimalist (MIN) follow-up regimen improves overall survival (OS) in patients undergoing operation for endometrial cancer.
A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets.
Herzog, Chiara PhD 1,2,,; Marin, Fatima PhD 3,4; Jones, Allison BSc 5; Evans, Iona PhD 5; Reisel, Daniel PhD 5; Redl, Elisa MSc 1,2; Schreiberhuber, Lena MSc 1,2; Paytubi, Sonia PhD 6; Pelegrina, Beatriz MSc 6; Carmona, Alvaro PhD 6; Peremiquel-Trillas, Paula MD 6,; Frias-Gomez, Jon MSc 6; Pineda, Marta PhD 3,4; Brunet, Joan MD, PhD 3,4,7,; Ponce, Jordi PhD 4,8,; Matias-Guiu, Xavier PhD 4,9,; de Sanjose, Silvia PhD 10; Alemany, Laia PhD 6,11,; Olaitan, Adeola MD 12; Wong, Michael PhD 12; Jurkovic, Davor PhD 12; Crosbie, Emma J. MD 13,14; Rosenthal, Adam N. PhD 5,; Bjorge, Line PhD 15,16; Zikan, Michal PhD 17; Dostalek, Lukas MD, PhD 18; Cibula, David PhD 18,; Sundstrom, Karin PhD 19,; Dillner, Joakim PhD 19; Costas, Laura PhD 6,11,; Widschwendter, Martin MD 1,5,2,20,,
doi : 10.1200/JCO.22.00266
AB PURPOSE: Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival.
Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321).
Dunkel, Ira J. MD 1,,; Piao, Jin PhD 2; Chantada, Guillermo L. MD 3,; Banerjee, Anuradha MD 4,; Abouelnaga, Sherif MD 5; Buchsbaum, Jeffrey C. MD, PhD 6; Merchant, Thomas E. DO, PhD 7,; Granger, Meaghan M. MD 8; Jubran, Rima F. MD 9; Weinstein, Joanna L. MD 10; Saguilig, Lauren MS 11; Abramson, David H. MD 1; Krailo, Mark D. PhD 2,; Rodriguez-Galindo, Carlos MD 7; Chintagumpala, Murali M. MD 12
doi : 10.1200/JCO.21.02337
Metastatic retinoblastoma has a poor prognosis when treated with conventional chemotherapy and radiation therapy (RT). Intensified therapy may improve the outcome. METHODS: A prospective, international trial enrolled patients with extraocular retinoblastoma.
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Kadia, Tapan M. MD 1,,; Reville, Patrick K. MPH, MD 2; Wang, Xuemei MS 3; Rausch, Caitlin R. PharmD 4; Borthakur, Gautam MD 1,; Pemmaraju, Naveen MD 1,; Daver, Naval G. MD 1,; DiNardo, Courtney D. MD, MSCE 1,; Sasaki, Koji MD, PhD 1,; Issa, Ghayas C. MD 1,; Ohanian, Maro MD 1,; Montalban-Bravo, Guillermo MD 1,; Short, Nicholas J. MD 1,; Jain, Nitin MD 1,; Ferrajoli, Alessandra MD 1,; Bhalla, Kapil N. MD 1; Jabbour, Elias MD 1,; Takahashi, Koichi MD, PhD 1,; Malla, Rashmi BSN 1; Quagliato, Kelly BS 1; Kanagal-Shamanna, Rashmi MD 5,; Popat, Uday R. MD 6,; Andreeff, Michael MD, PhD 1,; Garcia-Manero, Guillermo MD 1,; Konopleva, Marina Y. MD, PhD 1,; Ravandi, Farhad MD 1,; Kantarjian, Hagop M. MD 1,
doi : 10.1200/JCO.21.02823
The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates and survival compared with 5-AZA alone. We hypothesized that the addition of venetoclax to cladribine (CLAD)/low-dose araC (low-dose cytarabine [LDAC]) alternating with 5-AZA backbone may further improve outcomes for older patients with newly diagnosed AML.
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.
Yang, Jonathan T. MD, PhD 1,,; Wijetunga, N. Ari MD, PhD 1; Pentsova, Elena MD 2; Wolden, Suzanne MD 1; Young, Robert J. MD 3,; Correa, Denise PhD 2; Zhang, Zhigang PhD 4; Zheng, Junting MS 4; Steckler, Alexa BS 1,; Bucwinska, Weronika BS 1; Bernstein, Ashley CTN 1; Betof Warner, Allison MD, PhD 5,; Yu, Helena MD 6,; Kris, Mark G. MD 6,; Seidman, Andrew D. MD 7,; Wilcox, Jessica A. MD 2; Malani, Rachna MD 2; Lin, Andrew MD 2,; DeAngelis, Lisa M. MD 2,; Lee, Nancy Y. MD 1,; Powell, Simon N. MD, PhD 1,; Boire, Adrienne MD, PhD 2,8,
doi : 10.1200/JCO.22.01148
Photon involved-field radiotherapy (IFRT) is the standard-of-care radiotherapy for patients with leptomeningeal metastasis (LM) from solid tumors. We tested whether proton craniospinal irradiation (pCSI) encompassing the entire CNS would result in superior CNS progression-free survival (PFS) compared with IFRT.
Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.
Kim, Seung Tae MD, PhD 1; Kim, Sun Young MD, PhD 2,3,; Lee, Jeeyun MD, PhD 1,; Yun, Seong Hyeon MD, PhD 1; Kim, Hee Cheol MD, PhD 1; Lee, Woo Yong MD, PhD 1; Kim, Tae Won MD, PhD 2,; Hong, Yong Sang MD, PhD 2; Lim, Seok-Byung MD, PhD 2; Baek, Ji Yeon MD, PhD 3; Oh, Jae Hwan MD, PhD 3; Ahn, Joong Bae MD, PhD 4; Shin, Sang Joon MD, PhD 4; Han, Sae-Won MD, PhD 5; Kim, Seong Geun MD, PhD 6; Kang, Seok Yun MD, PhD 7; Sym, Sun Jin MD, PhD 8; Zang, Dae Young MD, PhD 9; Kim, Yeul Hong MD, PhD 10,; Choi, In Sil MD, PhD 11; Kang, Jung Hun MD, PhD 12; Kim, Min-Ji MD, PhD 13; Park, Young Suk MD, PhD 1,
doi : 10.1200/JCO.21.02962
The combination of oxaliplatin and fluoropyrimidine for 6 months is one of the standard options for adjuvant therapy for high-risk stage II and III colorectal cancers (CRCs). The optimal duration of oxaliplatin to diminish neurotoxicity without compromising efficacy needs to be clarified.
Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
Tew, William P. MD 1; Lacchetti, Christina MHSc 2; Kohn, Elise C. MD 3; for the PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel
doi : 10.1200/JCO.22.01934
AB ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. (C) 2022 American Society of Clinical Oncology
Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy.
Hertz, Daniel L. PharmD, PhD 1,,
doi : 10.1200/JCO.22.00037
Patients who carry pathogenic variants in DPYD have higher systemic fluoropyrimidine (FP) concentrations and greater risk of severe and fatal FP toxicity. Pretreatment DPYD testing and DPYD-guided FP dosing to reduce toxicity and health care costs is recommended by European clinical oncology guidelines and has been adopted across Europe, but has not been recommended or adopted in the United States.
Locoregional Therapy for Intact Primary Tumor in De Novo Stage IV Breast Cancer.
Soran, Atilla MD, MPH, FNCBC; Aytac, Ozgur MD, FEBS; Ozbas, Serdar MD, FEBS
doi : 10.1200/JCO.22.00802
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
Ulas Kahya, Burcu MD; Sutcuoglu, Osman MD; Yaz[latin dotless i]c[latin dotless i], Ozan MD; Ozdemir, Nuriye MD
doi : 10.1200/JCO.22.00404
Reply to B. Ulas Kahya et al and A. Soran et al.
Khan, Seema Ahsan MPH, MD; Zhao, Fengmin MD; Goldstein, Lori MD; Sparano, Joseph MD; Sledge, George MD
doi : 10.1200/JCO.22.00861
